KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average) (2016 - 2025)

Sarepta Therapeutics (SRPT) has 11 years of Shares Outstanding (Weighted Average) data on record, last reported at $97.7 million in Q2 2025.

  • For Q2 2025, Shares Outstanding (Weighted Average) rose 3.58% year-over-year to $97.7 million; the TTM value through Jun 2025 reached $97.7 million, up 3.58%, while the annual FY2021 figure was $81.3 million, 4.24% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $97.7 million in Q2 2025 per SRPT's latest filing, up from $94.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $97.7 million in Q2 2025 and bottomed at $79454.0 in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $62.5 million, with a median of $84.9 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 99.9% in 2021, then rose 9.82% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $81.3 million in 2021, then plummeted by 99.89% to $87253.0 in 2022, then surged by 101454.1% to $88.6 million in 2023, then increased by 6.84% to $94.7 million in 2024, then grew by 3.19% to $97.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $97.7 million in Q2 2025, $94.7 million in Q3 2024, and $94.3 million in Q2 2024.